Indapamide

By X. Keldron. State University of New York Institute of Technology at Canton.

Disease-modifying drugs for multiple sclerosis Page 95 of 120 Final Report Update 1 Drug Effectiveness Review Project 178 purchase indapamide 2.5mg with mastercard. Long-term follow up of glatiramer acetate compassionate use in Belgium purchase indapamide 2.5mg on-line. Flechter S discount indapamide 1.5mg without a prescription, Kott E purchase 2.5 mg indapamide overnight delivery, Steiner-Birmanns B, Nisipeanu P, Korczyn AD. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. New insights into progressive multifocal leukoencephalopathy. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis. Disease-modifying drugs for multiple sclerosis Page 96 of 120 Final Report Update 1 Drug Effectiveness Review Project 195. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Wolinsky JS, Shochat T, Weiss S, Ladkani D, Group PRTS. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. Disease-modifying drugs for multiple sclerosis Page 97 of 120 Final Report Update 1 Drug Effectiveness Review Project Appendix A. Glossary This glossary defines terms as they are used in reports produced by the Drug Effectiveness Review Project.

order 1.5 mg indapamide

Treatment of vasomotor symptoms of menopause with black cohosh indapamide 2.5mg, multibotanicals buy indapamide 1.5 mg line, soy buy generic indapamide 2.5 mg line, hormone therapy generic 2.5 mg indapamide with visa, or placebo: a randomized trial. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric : the journal of the International Menopause Society. Speroff L, Haney AF, Gilbert RD, Ellman H, Estradiol Acetate Investigator G. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Speroff L, Symons J, Kempfert N, Rowan J, femhrt Study I. The effect of varying low- dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomized placebo controlled pilot cross-over study. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. Estradiol or estradiol/progesterone treatment in older women: no strong effects on cognition. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Bech P, Munk-Jensen N, Obel EB, Ulrich LG, Eiken P, Nielsen SP. Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on Hormone therapy Page 62 of 110 Final Report Update 3 Drug Effectiveness Review Project quality of life-related outcome measures. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Quality of life during sequential hormone replacement therapy -- a placebo-controlled study. International Journal of Fertility & Menopausal Studies. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta- estradiol dose for treating vasomotor symptoms. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Vikhlyaeva E, Zaidiieva Y, Lobova T, Shishkina A, Larsen S. Trisequens in perimenopausal women with climacteric syndrome: a randomized double-blind trial [abstract]. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: A placebo-controlled study. Effects of period-free hormone replacement therapy in postmenopausal women in Taiwan. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Blumel JE, Roncagliolo ME, Gramegna G, Vasquez R, Estartus AT. Jensen PB, Jensen J, Riis BJ, Rodbro P, Strom V, Christiansen C.

purchase 1.5 mg indapamide free shipping

Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus 2 in elective cesarean delivery buy 1.5 mg indapamide amex. The effectiveness of inhalation isopropyl alcohol vs granisetron for the prevention of postoperative nausea and vomiting buy generic indapamide 1.5mg. Placebo-controlled trials Antiemetics Page 134 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded studies code # Bano F buy generic indapamide 1.5 mg, Zafar S generic indapamide 2.5mg free shipping, Aftab S, Haider S. Dexamethasone plus ondansetron for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a comparison with dexamethasone alone. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. A randomized, double-blind, close- ranging, pilot study of intravenous granisetron in the prevention of 2 postoperative nausea and vomiting in patients abdominal hysterectomy. The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients 2 after ear-nose-throat surgery. Oral ondansetron for gastroenteritis in a pediatric emergency department. The efficacy of postoperative ondansetron (Zofran) orally disintegrating tablets for preventing nausea and vomiting after 2 acoustic neuroma surgery. Jellish WS, Leonetti JP, Sawicki K, Anderson D, Origitano TC. Morphine/ondansetron PCA for postoperative pain, nausea, and vomiting 4 after skull base surgery. A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 2 1- to 24-month-old pediatric patients after surgery under general anesthesia. Kocamanoglu IS, Baris S, Karakaya D, Sener B, Tur A, Cetinkaya M. Effects of granisetron with droperidol or dexamethasone on prevention of postoperative nausea and vomiting after general anesthesia for cesarean 2 section. Methods & Findings in Experimental & Clinical Pharmacology. Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C, Palonosetron 04-07 Study G. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing 2 postoperative nausea and vomiting over a 72-hour period. Scheduled prophylactic ondansetron administration did not improve its antiemetic efficacy after 2 intracranial tumour resection surgery in children. Coronary vasospasm leading to an acute myocardial infarction after the administration of dolasetron. Antiemetics Page 135 of 136 Final Report Update 1 Drug Effectiveness Review Project Exclusion Excluded studies code # Einhorn LH, Brames, M. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea adn vomiting in patients receiving multiple- 6 day cisplatin chemotherapy for germ cell cancer. Hasler SB, Hirt A, Ridolfi Luethy A, Leibundgut KK, Ammann RA. Safety of ondansetron loading doses in children with cancer. A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and 3 vomiting: a Hoosier oncology group study. Economic evaluation of ondansetron vs dimenhydrinate for prevention of postoperative vomiting in 2 children undergoing strabismus surgery. Placental transfer of ondansetron during early 3 human pregnancy. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents [Systematic Review]. Drugs for preventing postoperative nausea and vomiting [Systematic Review]. Meta-analysis of its effectiveness in patients with previous history of 6 postoperative nausea and vomiting. Gupta A, Wu CL, Elkassabany N, Krug CE, Parker SD, Fleisher LA. Does the routine prophylactic use of antiemetics affect the incidence of postdischarge 6 nausea and vomiting following ambulatory surgery? Huang JQ, Zheng GF, Chan GC, Karlberg J, Lam SK, Wong BC. Efficacy of current antietmetic treatment for preventing delayed chemotherapy-induced 6 nausea and vomiting: a meta-analysis of randomized controlled trials. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a 6 meta-analysis. Antiemetics Page 136 of 136 Drug Class Review Newer Antiemetics Final Report Update 1 Evidence Tables January 2009 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

order indapamide 1.5mg overnight delivery

discount 2.5mg indapamide

Placebo controlled trials of beta blockers for heart failure Author Method of Year Number screened/ Number withdrawn/ adverse effects Country eligible/enrolled lost to fu/analyzed Outcomes assessment? Richards Screened: NR Total withdrawn at 6 months: Primary: NR 2001 Eligible for run-in: 442 43/415 (10%)/lost to fu Anonymous Enrolled: 415 NR/analyzed=415 No significant improvement in treadmill duration 1995 order indapamide 2.5mg mastercard, 1997 car (n= 207) Secondary: Australia/New pla (n= 208) No significant improvement in 6-min order 1.5mg indapamide with mastercard. Placebo controlled trials of beta blockers for heart failure Author Year Withdrawals due to adverse events (% indapamide 2.5 mg for sale, adverse Country Adverse effects reported n/enrolled n) Comments Richards nr Withdrawals due to: 2001 Dizziness/Hypotension: Anonymous car: 3/207 (1 buy indapamide 1.5 mg lowest price. Placebo controlled trials of beta blockers for heart failure Author Year Mean EF Country NYHA Class Eligibility criteria Cleland, 2003 29. Placebo controlled trials of beta blockers for heart failure Author Year Interventions (drug, regimen, Country Exclusion criteria duration) Cleland, 2003 Patients younger than 40 years and women of child-bearing age; Carvedilol (car) 6. Placebo controlled trials of beta blockers for heart failure Author Age Other population Year Allowed other Method of outcome assessment Gender characteristics Country medications/interventions and timing of assessment Ethnicity (diagnosis, etc) Cleland, 2003 Angiotensin-converting enzyme Primary: Change in LVEF in Age: 62. Placebo controlled trials of beta blockers for heart failure Author Method of Year Number screened/ Number withdrawn/ adverse effects Country eligible/enrolled lost to fu/analyzed Outcomes assessment? Placebo controlled trials of beta blockers for heart failure Author Year Withdrawals due to adverse events (%, adverse Country Adverse effects reported n/enrolled n) Comments Cleland, 2003 Overall adverse events: frequent in both nr groups (rates NR) Carvedilol Hibernating Reversible Ischaemia Dizziness, fatigue, syncope and bradycardia Trial: Marker of were more typical with carvedilol than with Success placebo (rates NR) (CHRISTMAS) Fair quality Eichhorn Serious adverse events: pla=516(45. Placebo controlled trials of beta blockers for heart failure Author Year Mean EF Country NYHA Class Eligibility criteria Hori LVEF=30% Patient who had ischemic or nonischemic cardiomyopathy with 2004 NYHA class stable symptoms (NYHA functional class II or III); LVEF ≤ 40%; age Japan II/III=78% between 20 and 79 years The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) Trial Fair quality Beta blockers Page 215 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Year Interventions (drug, regimen, Country Exclusion criteria duration) Hori Valvular heart disease, hypertrophic obstructive cardiomyopathy, Run-in 2004 cardiogenic shock, systolic blood pressure < 90 mm Hg, bradycardia Open carvedilol 2. Placebo controlled trials of beta blockers for heart failure Author Age Other population Year Allowed other Method of outcome assessment Gender characteristics Country medications/interventions and timing of assessment Ethnicity (diagnosis, etc) Hori Diuretics, digitalis, ACE inhibitors, Primary: Improvement of global Mean age=60 Nonischemic etiology of 2004 calcium channel blockers, assessment of CHF by attending 77% male heart failure=73% Japan vasodilators, anti-arrhythmic physician (markedly improved, 100% Japanese NYHA class II/III=78% agents moderately improved, mildly LVEF=30% The Multicenter improved, no change, worsened, Systolic BP (mm HG)=119 Carvedilol Heart unassessable) Diastolic BP (mm Hg)=72 Failure Dose Secondary: all-cause death or Heart rate (beats/min)=80 Assessment hospitalization for cardiovascular Body weight=61 kg (MUCHA) Trial disease (CVD), CVD Other medications hospitalization, hospitalization for ACE-inhibitors=76% Fair quality worsening CHF, changes of LVEF, Diuretics=86% and changes of NYHA class Digitalis=65% Beta blockers Page 217 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Method of Year Number screened/ Number withdrawn/ adverse effects Country eligible/enrolled lost to fu/analyzed Outcomes assessment? Placebo controlled trials of beta blockers for heart failure Author Year Withdrawals due to adverse events (%, adverse Country Adverse effects reported n/enrolled n) Comments Hori Incidence: 63. Placebo controlled trials of beta blockers for heart failure Author Year Mean EF Country NYHA Class Eligibility criteria Metoprolol Anderson 28% Idiopathic dilated cardiomyopathy confirmed by ECG 1985 NYHA class avg: 2. Placebo controlled trials of beta blockers for heart failure Author Year Interventions (drug, regimen, Country Exclusion criteria duration) Metoprolol Anderson Unstabilized overt cardiac failure; alcohol abuse; secondary Metoprolol (met) 100 mg daily 1985 cardiomyopathies; firm exclusions to beta blocker treatment (asthma, Placebo (pla) x 19 months advanced heart block, allergy) Begin 12. Fair quality Beta blockers Page 221 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Age Other population Year Allowed other Method of outcome assessment Gender characteristics Country medications/interventions and timing of assessment Ethnicity (diagnosis, etc) Metoprolol Anderson Digitalis: 87% Primary: Survival Mean age 51 NR 1985 Diuretic: 80% Vasodilators: 40% 66% male Antiarrhythmics: 35% Secondary: Exercise duration USA Anticoagulant (warfarin): 12% (Naughton protocol) Race NR Fair quality Beta blockers Page 222 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Method of Year Number screened/ Number withdrawn/ adverse effects Country eligible/enrolled lost to fu/analyzed Outcomes assessment? Metoprolol Anderson Screened: NR Dropout from treatment group: Primary NR 1985 Eligible: 50 5/25 (20%) Deaths: Enrolled: 50 met: 5/25 (20%) Overall, 2 patients lost to follow-up pla: 6/25 (24%) (NS) USA met (n=25) pla (n=25) Analyzed=50 Secondary Fair quality Exercise duration: met: 9. Placebo controlled trials of beta blockers for heart failure Author Year Withdrawals due to adverse events (%, adverse Country Adverse effects reported n/enrolled n) Comments Metoprolol Anderson NR NR 1985 USA Fair quality Beta blockers Page 224 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Year Mean EF Country NYHA Class Eligibility criteria Waagstein 22% 16-75 years; symptomatic dilated cardiomyopathy; state of 1993 compensated heart failure by means of conventional treatment; NYHA class systolic BP >90 mm Hg; heart rate >45 beats per minute Metoprolol in Dilated I: 3% Cardiomyopathy II: 45% (MDC) Trial III: 49% IV: 4% Fair quality Beta blockers Page 225 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Year Interventions (drug, regimen, Country Exclusion criteria duration) Waagstein Treatment with beta blockers, calcium channel blockers, inotropic Metoprolol (met) 100-150 mg daily 1993 agents or high doses of tricyclic antidepressant drugs; significant CAD (higher target for higher weight) vs. Begin 10 mg titrated over 6+ weeks to target - Fair quality mean dose 108 mg/day. Beta blockers Page 226 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Age Other population Year Allowed other Method of outcome assessment Gender characteristics Country medications/interventions and timing of assessment Ethnicity (diagnosis, etc) Waagstein Digitalis: 78% Primary Mean age 49 Current smokers: 18% 1993 ACEI: 79% Combined - total deaths and need Nitrates: 14% for transplantation. Beta blockers Page 227 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Method of Year Number screened/ Number withdrawn/ adverse effects Country eligible/enrolled lost to fu/analyzed Outcomes assessment? Waagstein Screened: NR Withdrawn from study medication Primary NR 1993 Eligible: 417 at 12 months: Total deaths or need for transplantation: Enrolled: 383 54/383 (14%) met: 25/194 (12. Placebo controlled trials of beta blockers for heart failure Author Year Withdrawals due to adverse events (%, adverse Country Adverse effects reported n/enrolled n) Comments Waagstein NR Withdrawals due to: 1993 Progressive heart failure: met: 7/194 (3. Placebo controlled trials of beta blockers for heart failure Author Year Mean EF Country NYHA Class Eligibility criteria Anonymous 28% Age 40-80; symptomatic heart failure (NYHA class II-IV) for 3 months 1999 or more and receiving optimum standard therapy; stable clinical Goldstein NYHA class condition during 2 week run-in phase; LVEF of <40% 1999 II: 41% Hjalmarson III: 55% 2000 IV: 4% Goldstein 2001 Ghali 2002 Gottlieb 2002 Deedwania 2005 Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Fair quality Beta blockers Page 230 of 494 Final Report Update 4 Drug Effectiveness Review Project Evidence Table 9. Placebo controlled trials of beta blockers for heart failure Author Year Interventions (drug, regimen, Country Exclusion criteria duration) Anonymous Acute MI or unstable angina within 28 days; indication or Metoprolol (met) 200 mg/day vs. Goldstein planned or performed in the past 4 months; atrioventricular block of the 2001 second or third degree; unstable decompensated heart failure; supine Ghali systolic BP >100 mm Hg; any serious disease that might complicate 2002 management and follow-up according to protocol; use of calcium Gottlieb antagonists; use of amiodarone within 6 months; poor compliance. Placebo controlled trials of beta blockers for heart failure Author Age Other population Year Allowed other Method of outcome assessment Gender characteristics Country medications/interventions and timing of assessment Ethnicity (diagnosis, etc) Anonymous Diuretics: 90% Primary: Mean ages: Current daily smoker: 14. Placebo controlled trials of beta blockers for heart failure Author Method of Year Number screened/ Number withdrawn/ adverse effects Country eligible/enrolled lost to fu/analyzed Outcomes assessment? Anonymous Screened: NR Total withdrawn: 589/3991 (15%) Primary NR 1999 Eligible (recruited): 4427 All cause mortality: met=145(7. Subgroup: diabetic patients Total mortality risk reduction met vs pla: 18% (95% CI 44% to -19%; P>0. Placebo controlled trials of beta blockers for heart failure Author Year Withdrawals due to adverse events (%, adverse Country Adverse effects reported n/enrolled n) Comments Anonymous Withdrawals due to: 1999 Dizziness: Goldstein met: 12/1990 (0.

Indapamide
9 of 10 - Review by X. Keldron
Votes: 199 votes
Total customer reviews: 199